Statin use and the risk of Parkinson disease
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate associations between statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor) use and Parkinson disease (PD). METHODS: We used a population-based design to recruit 312 incident idiopathic PD cases and 342 controls from three rural California counties. RESULTS: We observed a higher frequency of statin use among controls vs cases (OR 0.45; 95% CI 0.29 to 0.71) and a strong dose-response relation. The strongest protective association between statin use and PD was observed in long-term (>or=5 years) users (OR 0.37; 95% CI 0.18 to 0.78). There was no difference by gender or age. We noted 60 to 70% risk reductions for each individual statin except pravastatin. CONCLUSION: Ascribing causality to these associations is premature and further studies are needed to confirm a potential neuroprotective role for statins in PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hughes, A. J., Ben-Shlomo, Y., Daniel, S. E., & Lees, A. J. (1992) · Neurology · doi:10.1212/wnl.42.6.1142 · Cited by 1,313
Langsjoen, P. H., & Langsjoen, A. M. (2003) · BioFactors · doi:10.1002/biof.5520180212 · Cited by 112
Cited by
The ongoing pursuit of neuroprotective therapies in Parkinson disease
Athauda, D., & Foltynie, T. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.226 · Cited by 269
Statins: Mechanisms of neuroprotection
van der Most, P. J., Dolga, A. M., Nijholt, I. M., Luiten, P. G. M., & Eisel, U. L. M. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.02.002 · Cited by 268
“Recent clinical studies also showed unexpected effects of statins on the incidence of Parkinson's disease (PD) (Huang et al., 2007; Wahner et al., 2008; Wolozin et al., 2007).”
Dysregulated Lipid Metabolism and Its Role in α-Synucleinopathy in Parkinson’s Disease
Alecu, I., & Bennett, S. A. L. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00328 · Cited by 258
Neuroprotective and Therapeutic Strategies against Parkinson’s Disease: Recent Perspectives
Sarkar, S., Raymick, J., & Imam, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060904 · Cited by 202
“Subsequent epidemiological study has demonstrated that people who are taking simvastin can lower the risk of having PD [98,180].”
BackgroundStatins: Multiple neuroprotective mechanisms in neurodegenerative diseases
Wang, Q., Yan, J., Chen, X., Li, J., Yang, Y., Weng, J., Deng, C., & Yenari, M. A. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2010.04.006 · Cited by 130
Metadata
- Authors
- Wahner, A. D., Bronstein, J. M., Bordelon, Y. M., & Ritz, B.
- Venue
- Neurology
- Published
- 2008-04-15
- Volume
- 70
- Issue
- 16_part_2
- Pages
- 1418-1422
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1994807176
- Cited by
- 129
- References
- 2
- FWCI
- 6.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Statin use and the risk of Parkinson disease. https://app.cochat.ai/papers/10.1212/01.wnl.0000286942.14552.51
- The paper
- Wahner, A. D., Bronstein, J. M., Bordelon, Y. M., & Ritz, B. (2008). Statin use and the risk of Parkinson disease. Neurology. https://doi.org/10.1212/01.wnl.0000286942.14552.51
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.